

## UNITED STATES DEPARTMENT OF COMMERCE United States Pat nt and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

AF	PPLICATION NO. FILING DATE FIRST NAMED INVENTOR		ATT	ATTORNEY DOCKET NO.			
	09/765,49	1 01/18/01	ARBISER		Ţ.	EU 98055 CON	
	023579	HM22/0727		$\neg$		EXAMINER	
	PATREA L. PABST HOLLAND & KNIGHT LLP				KIM, J		
		Q, ONE ATLAN	ITIC CENTER		ART UNIT	PAPER NUMBER	
	1201 WEST	PEACHTREE S	TREET, N.E.		1617	3	
	AILANIA G	A 30309-3400			DATE MAILED:	07/27/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

_		Application No.	Applicant(s)				
•		09/765,491	ARBISER, JACK L.				
	Office Action Summary	Examiner	Art Unit				
		Jennifer M Kim	1617				
: ۔۔ Period for I	The MAILING DATE of this communication app Reply	ears on the cover sheet with the c	orrespondence address				
THE MA - Extension after SIX - If the period of the period	RTENED STATUTORY PERIOD FOR REPLY ILLING DATE OF THIS COMMUNICATION.  IN SO IT THIS COMMUNICATIO	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).				
1)⊠ F	Responsive to communication(s) filed on 18 J	anuary 2001 .					
2a)∐ <b>1</b>	This action is FINAL. 2b) ☐ Thi	is action is non-final.					
	Since this application is in condition for allowallosed in accordance with the practice under it						
Disposition of Claims							
4)⊠ C	aim(s) 4-6 and 10-17 is/are pending in the a	pplication.					
4a	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)∏ C	aim(s) is/are allowed.						
6)□ C	aim(s) is/are rejected.						
7) 🗌 C	aim(s) is/are objected to.						
8)⊠ C	aim(s) $4-6$ , $10-17$ are subject to restriction ar	nd/or election requirement.					
Application	Papers						
9)□ Th	e specification is objected to by the Examine	r.					
10)∐ Th	e drawing(s) filed on is/are: a) accep	ited or b)⊡ objected to by the Exa	miner.				
,	Applicant may not request that any objection to the	e drawing(s) be held in abeyance. So	ee 37 CFR 1.85(a).				
11) 🔲 Th	e proposed drawing correction filed on	is: a) approved b) disappro	ved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.							
12)∐ Th	e oath or declaration is objected to by the Ex	aminer.					
Priority und	ler 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) <u></u> ☐	All b)☐ Some * c)☐ None of:						
1.	Certified copies of the priority documents	s have been received.					
2.	Certified copies of the priority documents	s have been received in Application	on No				
	Copies of the certified copies of the prior application from the International But the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).	_				
14)∐ Ack	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
, –	The translation of the foreign language pro						
Attachment(s)	_	-					
2) 🔲 Notice o	FReferences Cited (PTO-892)  FOR Draftsperson's Patent Drawing Review (PTO-948)  FOR Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				
S Datent and Trade							

Application/Control Number: 09/765,491

Art Unit: 1617

## Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 4-6, 10-12, and 17 drawn to a method for inhibiting skin disorders comprising an angiogenesis inhibitor.
  - II. Claims 13-16, drawn to a pharmaceutical composition comprising a curcumin in combination with a pharmaceutically acceptable carrier.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions Group I and Group II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that

product since the product has been used for treatment of bladder cancer.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Further restriction may be required.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is (703) 308-2232. The examiner can normally be reached on Monday through Friday from 9 AM. to 4 PM.

Application/Control Number: 09/765,491 Page 4

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Theodore J. Criares Primary Examiner Art Unit 1617

jmk July 25, 2001